Evidence map›Paper›PMID 37193311›Full record

ArticleChina CDC weekly2023

Genomic Recombination of SARS-CoV-2 Subvariants BA.5.2.48 and BF.7.14 - China, 2023.

Zhongxian Zhang, Han Li, Hongxia Ma, Wenling Wang, Dawei Gao, Fei Ye, Weibang Huo, Yuda Chen, Changcheng Wu, Wenjie Tan

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Surveillance of SARS-CoV-2 variants in Henan, China from 2023 to 2024.Frontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zhongxian ZhangNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Han LiSchool of Public Health, Baotou Medical College, Baotou City, Inner Mongolia Autonomous Region, China.
Hongxia MaHenan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan Province, China.
Wenling WangNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Dawei GaoLu'an Municipal Center for Disease Control and Prevention, Lu'an City, Anhui Province, China.
Fei YeNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Weibang HuoNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yuda ChenNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Changcheng WuNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Wenjie TanNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
National Institute for Viral Disease Control and Prevention · CNBaotou Medical College · CNHenan Provincial Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BA.5.2BF.7.14Genomic RecombinationSARS-CoV-2

Identifiers

PMID37193311
PMCPMC10182904
OpenAlexW4362710198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.